Anteris Technologies Global
- Market cap
- 664.67M
- P/E (TTM)i
- -3.50
- P/Bi
- 2.64
- EPSi
- -2.55
- Div yieldi
- 0.00%
- 52W posi
- 45%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Anteris Technologies Global (AVR) | 664.67M | -3.50 | 2.64 | 0.00% |
| Abbott Laboratories (ABT) | 170.84B | 31.95 | 3.34 | 2.47% |
| Medtronic (MDT) | 109.38B | 21.06 | 2.18 | 3.33% |
| Stryker Corp (SYK) | 105.64B | 28.54 | 4.40 | 1.26% |
| Boston Scientific (BSX) | 60.26B | 16.83 | 2.42 | 0.00% |
| Edwards Lifesciences (EW) | 49.44B | 49.87 | 4.66 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 13.7% below Morningstar's fair value estimate.
Fair value
Anteris Technologies Global Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $7.75 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's balance sheet increases our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 14.2 lies in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.
Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, a core component of profitability, sits in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 08:03:19 · For reference only, not investment advice and not tailored to your situation.